Brief: IGM Biosciences Announces FDA Clearance To Begin Clinical Studies Of Lupus And Rheumatoid Arthritis Treatment
31/05/2023 12:09
May 31 (Reuters) - IGM Biosciences Inc IGMS.O :
* IGM BIOSCIENCES ANNOUNCES FDA CLEARANCE TO BEGIN CLINICAL
STUDIES OF IMVOTAMAB IN LUPUS AND RHEUMATOID ARTHRITIS
* IGM BIOSCIENCES INC - PLANS TO BEGIN PATIENT ENROLLMENT IN
BOTH
MULTICENTER CLINICAL STUDIES IN Q3 OF 2023
Source text for Eikon: ID:nGNX7sZ9bq
Further company coverage: IGMS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IGM Biosciences
See all newsU.S. STOCKS ON THE MOVE-Energy stocks, Apple, Vertex
U.S. STOCKS ON THE MOVE-Snap, Solventum, GlobalFoundries
IGM Biosciences rises on buyout deal with Concentra Biosciences
Brief: Igm Biosciences Enters Into Agreement To Be Acquired By Concentra Biosciences For $1.247 In Cash Per Share Plus A Contingent Value Right
IGM Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary